*Ocata Daily Discussion* 1.0

Charles Schwab upgraded OCAT from a 'D' rating to a 'C' on Sept. 27th.

I guess it does to some extent. The rating equates basically from a sell to a rough hold, so it's still not enough to pique anyone's interest in buying. Ocat's reputation has a tremendous dampening effect on pps.
 
It's going to take an 'above and beyond' event to convince pps to go up. Until then it will continue to go up, and then sell off. It's the same story we had on the Otc just with bigger players now.

With Pfizer coming out with it's PR on it's 'Pioneering' hesc sheet setup and them mentioning being able to possibly get a therapy from it people are not about to jump into a bed with a small player in this field, especially as hard headed as management has been over the years. 

Hopefully the science will eventually run ahead of bad management and things will come to fruition, but in the world of 'Wall Street' this company is just still a pie in the sky dreamer.

It hit the 3.50 area but I still need to see more confirmation that this is the bottom, the 3.20 area is still calling out to be tested but we'll see.

I have been thinking about Mako and the shorts tonight and I keep asking myself "where's the risk for them at this point"? When I say risk, I'm only talking about it in terms of investing. I hope what they're doing involves a high amount of legal risk - rules obviously exist for a reason.

So, is there an investment risk now? I've seen a lot of posts on the charity fraud section of the Internet about these folks getting caught with their pants down and how amazing that sweet justice will be.

But why is that the assumed case? The short volume indicates this is a sustained tactic, and I believe it's pretty likely these people are covering on each and every dip along the way. So how much of the house's money are they playing with? Why would getting burned once offset the multitude of victories they've had?

Just thoughts rolling around in my head. Appreciate insight from those smarter than me on this crap. GLTA, and thanks to everyone for making a concerted effort to participate in debate and dialogue here instead of pushing an agenda of groupthink. Such a dangerous mentality.

Note: it's incredibly possible I'm overlooking what risks are involved in shorting. I've never done it. I'm also obviously speculating, but so are people who think the shorts will eventually feel the wrath of Ocata.

Definitely in a bear market for now. There is a good chance yesterday's up move was shorts covering. 

www.fierceanimalhealth.com/story/stem-cell-treatment-proves-promising-dogs-crohns-disease/2015-10-02


*credit to CrystalMind, Thanks!

VetMed JV, where are you?

To be realistic...ONCE, successful Phase 3 trial with expected market approval next year vs OCAT just now starting Phase 2 with maybe commercialization in 2019.  Apples and oranges.

recapitulate = engraftment

www.freepatentsonline.com/EP2929782A1.html

Very Nice!

It discusses Parkinson's in the FIELD OF THE INVENTION as well as in the example below. Again, I'm not sure we should read much into it as I think much of this was written in 2005? That is my understanding at least

Example 10

Use of RPE cells for treatment of Parkinson's Disease.

[0085] hRPE can be used as an alternative source of cells for cell therapy of Parkinson's Disease because they secrete L-DOPA. Studies have showed that such cells attached to gelatin-coated microcarriers can be successfully transplanted in hemiparkinsonian monkeys and produced notable improvements (10-50) thousand cells per target), and in FDA-approved trial started in 2000 the patients received hRPE intrastriatial transplants without adverse effects. One of the many advantages to the use of hES cell-derived RPE is that it circumvents the shortage of donor eye tissue. It also facilitates the use of gene therapy.